CD47 expression is increased on disseminated lymphoma cells compared with primary lesions. (A) DLBCL cells from patient sample NHL7 were engrafted subcutaneously into NSG mice where they eventually disseminated to the bone marrow. Three weeks after transplantation, engrafted human lymphoma cells from the primary subcutaneous injection site and from secondary bone marrow disease were profiled for CD47 expression by flow cytometry (representative plot shown). CD47 expression was analyzed on human CD45⁺CD19⁺ cells. (B) CD47 expression was increased on lymphoma cells from the primary engraftment site compared with bone marrow metastases (P = .026, t test) when a panel of engrafted mice was profiled (n = 3 in each group). Data are mean ± SD. (C) When analyzing a panel of NHL patient samples, CD47 protein expression was increased on lymphoma cells from peripheral blood compared with lymph node. Normalized mean expression (and range) was determined for lymph node 584.0 (229.5-1142.0) and peripheral blood 1234.0 (745.0-1556). Each symbol represents a distinct NHL sample (supplemental Table 1). *P < .05. ***P < .0005.